Unilateral vs bilateral lung volume reduction surgery for emphysema
Official title: Unilateral Versus Bilateral Lung Volume Reduction Surgery for Patients With Severe COPD
Run by Copenhagen University Hospital, Rigshospitalet · NCT07731958 · Data updated 2026-11-12
This trial tests whether operating on one lung or both lungs provides better breathing and quality of life for adults with severe emphysema due to COPD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 146 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Locations | 1 site (Copenhagen) |
| Status | Recruiting |
| Started | March 21, 2025 |
| Main results expected | July 2031 |
| Study ends | July 2032 |
| Registry record updated | July 28, 2026 |
| Trial ID | NCT07731958 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with moderate to severe COPD and severe emphysema who are candidates for LVRS and have suitable target areas in both lungs.
✕Probably not a fit
Patients who are not likely to benefit include those with significant comorbidities, poor overall fitness, or lack of suitability for bilateral surgery.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial compares unilateral LVRS to bilateral LVRS in adults with moderate to severe COPD and severe emphysema. It uses modern surgical techniques and enhanced recovery practices to evaluate outcomes related to lung function, exercise capacity, and recovery. The study aims to provide up-to-date, randomized-like evidence to determine which approach yields greater benefit with acceptable risk. Eligible participants must meet standard LVRS criteria and be suitable for surgery and rehabilitation, with Danish or English language ability. Primary objectives focus on comparative effectiveness and safety of the two surgical approaches.
Why it matters
Potential benefit: If successful, the trial could clarify which surgical approach offers the best balance of lung function and recovery for patients with severe emphysema.
How similar studies have gone: Previous non-randomized data suggested bilateral LVRS might be superior, but modern techniques and ERAS protocols require fresh evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suitable target areas in both lungs * Age ≥ 18 years. * Speaks and understands Danish or English * Informed consent obtained * Usual inclusion criteria in LVRS: Moderate to severe COPD with MRC score \> 2 \< 75 years old 17 \< BMI \> 30 FEV1 \> 20% and \< 45% of predicted RV \> 200% of predicted as a sign of relevant hyperinflation DLCO \> 20% of predicted The patient should be in ideal medical treatment and have completed rehabilitation A high-resolution CT \< 3 months old should follow the referral to MDT Absence of nodules suspicious of malignancy on CT scan Absence of significant comorbidity including severe cardiovascular disease LVEF normal Absence of pulmonary hypertension, TI-gradient \< 40 mmHg Absence of chronic or frequent lung infections Smoking abstinence six months prior to surgery Assessed as sufficiently physically fit to undergo surgery and rehabilitation Exclusion Criteria: * Dependent on wheelchair * Living in nursery home * Dependent on walker device * Psychiatric disorder (anxiety, depression, schizophrenia) * Simultaneous lung cancer surgery * Massive adhesions during surgery assessed by the surgeon indicating problems postoperatively * Increased risk of post-operative bleeding assessed perioperatively by the surgeon. * Perioperative decision on not doing operation on the other side (medical, surgical or anaesthesiologic problems that favours a fast termination of the surgery, decided by the team in OR). * Previous cardiothoracic surgery * Increased bleeding risk (e.g., preoperative INR \>2, overdue discontinuation of anticoagulants according to guidelines by the Danish Society for Thrombosis and Haemostasis, known coagulopathy).
Where it's running
-
Rigshospitalet
Copenhagen, Denmark Recruiting
Study contacts
- Study coordinator: Alberte Lund, MD
- Email: alberte.lund@regionh.dk
- Phone: +4535458016
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endobronchial thermal liquid ablation for treating emphysema
This study is testing a new treatment called endobronchial thermal liquid ablation to see if it can safely help people with severe emphysema breathe better and improve their quality of life.
-
Using AeriSeal to treat collateral ventilation in severe emphysema patients
This study is testing if the AeriSeal treatment can help people with severe emphysema breathe better by improving airflow in their lungs.
-
Oral switch for bloodstream infections in immunocompromised children
This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.
-
Proton Therapy for Mediastinal Lymphoma in Denmark
This study tests whether using proton therapy for mediastinal lymphoma can lower late-toxicity risk compared with photon therapy in adults.
-
Oral switch for kids with bloodstream infections after starting IV therapy
This trial will test whether switching from IV to oral antibiotics early is not worse than continuing IV treatment for previously healthy children and teens with uncomplicated bloodstream infections.
-
Scar remodeling after burn injury using stem cells from fat tissue
This trial tests whether injecting allogeneic adipose-derived stem cells into burn scars can improve scar quality for adults with hypertrophic scars.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.